 Syndecan-1
"Syndecan-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A syndecan that interacts with EXTRACELLULAR MATRIX PROTEINS and plays a role CELL PROLIFERATION and CELL MIGRATION.
| Descriptor ID |
D053668
|
| MeSH Number(s) |
D12.776.395.550.847.100 D12.776.395.650.350.500.100 D12.776.543.550.847.100 D23.050.301.264.035.916 D23.101.100.110.940
|
| Concept/Terms |
Syndecan-1- Syndecan-1
- Syndecan 1
- CD138 Antigens
- Antigens, CD138
- CD138 Antigen
- Antigen, CD138
|
Below are MeSH descriptors whose meaning is more general than "Syndecan-1".
Below are MeSH descriptors whose meaning is more specific than "Syndecan-1".
This graph shows the total number of publications written about "Syndecan-1" by people in UAMS Profiles by year, and whether "Syndecan-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2021 | 0 | 2 | 2 | | 2020 | 0 | 2 | 2 | | 2017 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2013 | 0 | 4 | 4 | | 2012 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2007 | 2 | 0 | 2 | | 2006 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2003 | 0 | 6 | 6 | | 2002 | 0 | 5 | 5 | | 2001 | 0 | 2 | 2 | | 2000 | 0 | 1 | 1 | | 1999 | 0 | 3 | 3 | | 1997 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Syndecan-1" by people in Profiles over the past ten years.
-
Sallee CJ, Hippensteel JA, Miller KR, Oshima K, Pham AT, Richter RP, Belperio J, Sierra YL, Schwingshackl A, Mourani PM, Schmidt EP, Sapru A, Maddux AB. Endothelial Glycocalyx Degradation Patterns in Sepsis-Associated Pediatric Acute Respiratory Distress Syndrome: A Single Center Retrospective Observational Study. J Intensive Care Med. 2024 Mar; 39(3):277-287.
-
Boyle EM, Rosenthal A, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Davies FE, Walker BA, van Rhee F, Morgan GJ. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. Br J Haematol. 2021 10; 195(2):283-286.
-
Wong KY, Morgan GJ, Boyle EM, Cheng ASL, Yip KY, Chim CS. A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. Sci Rep. 2021 03 26; 11(1):7009.
-
Chen J, Gao XM, Zhao H, Cai H, Zhang L, Cao XX, Zhou DB, Li J. A highly heterogeneous mutational pattern in POEMS syndrome. Leukemia. 2021 04; 35(4):1100-1107.
-
Dhodapkar MV, Sexton R, Hoering A, Van Rhee F, Barlogie B, Orlowski R. Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clin Cancer Res. 2020 11 15; 26(22):5814-5819.
-
Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, Frech I, Tricot G, Zhan F. Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine. 2017 Apr; 18:41-49.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|